Skip to content

Treating drug dependence with the aid of ibogaine: A qualitative study

Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre, Bruno Daniel Rasmussen Chaves, Luís Fernando Tófoli, Dartiu Xavier Da Silveira

Journal of Psychedelic Studies April 1, 2017 DOI: 10.1556/2054.01.2016.002 via OpenAlex

Summary

AI-generated from the abstract

A treatment combining the psychedelic alkaloid ibogaine with cognitive-behavioral therapy led to improvements in craving, personal relationships, quality of life, and self-efficacy among people with substance use disorders, including cocaine dependence. These secondary outcomes were assessed through semi-structured interviews and qualitative content analysis. The findings support the therapeutic potential of ibogaine-assisted psychotherapy for treating substance use disorders, particularly for psychostimulants like cocaine and crack cocaine, for which effective treatments are lacking.

Study at a glance

Characteristics Qualitative study Peer reviewed
Population Patients with substance use disorders, including psychostimulant users
Interventions Ibogaine cognitive-behavioral therapy
Topics Addiction
Keywords Craving Abstinence Drug Psychiatry Clinical psychology
Citations 29
Key finding Patients receiving ibogaine combined with cognitive-behavioral therapy reported decreases in craving and improvements in personal relationships, quality of life, and self-efficacy.

Abstract

Substance use disorders are important contributors to the global burden of disease, but current treatments are not associated with high rates of recovery. The lack of approved and effective treatments is acutely problematic for psychostimulants like cocaine and crack cocaine. One promising alternative in the treatment of drug dependence in general and psychostimulants in particular is the use of the psychedelic alkaloid ibogaine combined with psychotherapy. This was recently shown to induce prolonged periods of abstinence in polydrug users, including psychostimulants. However, drug dependence treatments cannot be comprehensively evaluated with reductions in consumption alone, with current recommendations including secondary outcome measures like craving, family and social relationship, quality of life, and self-efficacy. We therefore employed a directed approach to qualitative content analysis to evaluate the outcomes of a treatment combining ibogaine with cognitive-behavioral therapy based on data gathered from patient's reports obtained in semi-structured interviews. The results revealed that patients benefited from the treatment in all the secondary outcomes, reporting decreases in craving and improvements in personal relationships, quality of life, and self-efficacy, thus supporting existing notions that treatments combining ibogaine and psychotherapy do have a therapeutic potential in the treatment of substance use disorders.

Explore topics

Comments

No comments yet.

Log in to comment